Home Cart 0 Sign in  
X

[ CAS No. 1445-73-4 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type HazMat fee for 500 gram (Estimated)
Excepted Quantity USD 0.00
Limited Quantity USD 15-60
Inaccessible (Haz class 6.1), Domestic USD 80+
Inaccessible (Haz class 6.1), International USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic USD 100+
Accessible (Haz class 3, 4, 5 or 8), International USD 200+
3d Animation Molecule Structure of 1445-73-4
Chemical Structure| 1445-73-4
Chemical Structure| 1445-73-4
Structure of 1445-73-4 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 1445-73-4 ]

Related Doc. of [ 1445-73-4 ]

Alternatived Products of [ 1445-73-4 ]

Product Details of [ 1445-73-4 ]

CAS No. :1445-73-4 MDL No. :MFCD00006191
Formula : C6H11NO Boiling Point : -
Linear Structure Formula :- InChI Key :HUUPVABNAQUEJW-UHFFFAOYSA-N
M.W : 113.16 Pubchem ID :74049
Synonyms :

Calculated chemistry of [ 1445-73-4 ]

Physicochemical Properties

Num. heavy atoms : 8
Num. arom. heavy atoms : 0
Fraction Csp3 : 0.83
Num. rotatable bonds : 0
Num. H-bond acceptors : 2.0
Num. H-bond donors : 0.0
Molar Refractivity : 35.85
TPSA : 20.31 Ų

Pharmacokinetics

GI absorption : Low
BBB permeant : No
P-gp substrate : No
CYP1A2 inhibitor : No
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -7.19 cm/s

Lipophilicity

Log Po/w (iLOGP) : 1.54
Log Po/w (XLOGP3) : -0.28
Log Po/w (WLOGP) : -0.1
Log Po/w (MLOGP) : 0.07
Log Po/w (SILICOS-IT) : 1.1
Consensus Log Po/w : 0.47

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 1.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -0.37
Solubility : 48.8 mg/ml ; 0.431 mol/l
Class : Very soluble
Log S (Ali) : 0.31
Solubility : 233.0 mg/ml ; 2.06 mol/l
Class : Highly soluble
Log S (SILICOS-IT) : -0.82
Solubility : 17.0 mg/ml ; 0.151 mol/l
Class : Soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 0.0 alert
Leadlikeness : 1.0
Synthetic accessibility : 1.0

Safety of [ 1445-73-4 ]

Signal Word:Danger Class:3
Precautionary Statements:P210-P233-P240-P241-P242-P243-P280-P303+P361+P353-P370+P378-P403+P235-P501 UN#:1224
Hazard Statements:H225 Packing Group:
GHS Pictogram:

Application In Synthesis of [ 1445-73-4 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 1445-73-4 ]
  • Downstream synthetic route of [ 1445-73-4 ]

[ 1445-73-4 ] Synthesis Path-Upstream   1~49

  • 1
  • [ 1445-73-4 ]
  • [ 5570-77-4 ]
Reference: [1] Journal of the American Chemical Society, 1948, vol. 70, p. 1826
  • 2
  • [ 1445-73-4 ]
  • [ 106-52-5 ]
YieldReaction ConditionsOperation in experiment
66% With tetrakis[3,5-bis(trifluoromethyl)phenyl]boric acid bis(diethyl ether) complex; (bis[(2-dicyclohexylphosphino)ethyl]amine)cobalt(II)(CH2SiMe3); hydrogen In tetrahydrofuran at 25℃; for 65 h; In a typical experiment, complex 1 (6.1 mg, 10 tmol) and H[BAr’4].(Et2O)2 (10.1 mg, 10 tmol) were dissolved in THF (2.0 mE) in a 100 mE thick-walled glass vessel equipped with a TEFLON stopcock and a stir bar. The substrate (0.5 mmol) to be hydrogenated was then added. The vessel was degassed by freeze-pump-thaw and then hydrogen (1 or 4 atm) was added. The resulting solution was stirred at the desired temperature (25-60° C.) for the indicated reaction time. At the end of the reaction, the solvent was evaporated and the residue was passed through silica gel in a pipette. The solvent was removed under vacuum and the ‘H NMR spectrum of the crude product mixture was recorded in CDC13. Hydrogenation products were then isolated by column chromatography or preparative thin layer chromatography (“TLC”) using n-hexane/ethyl acetate (3:1, v/v) as an eluent. Isolated products were characterized by ‘H NMR and GCMS, with spectra matching those reported in the literature or authentic samples.
Reference: [1] Journal of Medicinal Chemistry, 1997, vol. 40, # 16, p. 2474 - 2481
[2] Patent: US2015/336862, 2015, A1, . Location in patent: Paragraph 0038; 0054
[3] Patent: US2767190, 1950, ,
[4] Patent: US2776293, 1950, ,
[5] Journal of the American Chemical Society, 1948, vol. 70, p. 1826
[6] Phytochemistry, 1999, vol. 52, # 5, p. 871 - 878
[7] Acta Crystallographica Section C: Crystal Structure Communications, 2003, vol. 59, # 2, p. o60-o61
[8] Organic Letters, 2008, vol. 10, # 20, p. 4697 - 4700
[9] Angewandte Chemie - International Edition, 2012, vol. 51, # 48, p. 12102 - 12106[10] Angew. Chem., 2012, p. 12077
[11] Chemical Communications, 2013, vol. 49, # 86, p. 10151 - 10153
  • 3
  • [ 1445-73-4 ]
  • [ 62-53-3 ]
  • [ 106-52-5 ]
  • [ 22261-94-5 ]
Reference: [1] Pharmaceutical Chemistry Journal, 2000, vol. 34, # 2, p. 76 - 78
  • 4
  • [ 1445-73-4 ]
  • [ 71-43-2 ]
  • [ 106-52-5 ]
  • [ 4972-68-3 ]
Reference: [1] Journal of the American Chemical Society, 1950, vol. 72, p. 3134,3135
  • 5
  • [ 1445-73-4 ]
  • [ 41838-46-4 ]
YieldReaction ConditionsOperation in experiment
100% With ammonium formate In methanol Step: 3A-1Synthesis of l-Methyl-piperidin-4-yIamineProcedure:Ammonium formate (2.226g, 0.035348mol) was added to a solution of 1 -Methyl- piperidin-4-one (lg, 0.008837mol) in MeOH and stirred for lOmins. 20percent Pd-C was added to this and the reaction mixture was heated at 60°C for 2hrs. The reaction was monitored by the TLC (10percent methanol in chloroform). The reaction mixture was filtered through celite bed, concentrated to afford lg (100percent yield) of l-Methyl-piperidin-4-ylamine.
1.4 g With palladium 10% on activated carbon; ammonium formate In methanol; water at 20℃; for 24 h; Ammonium formate (15.4 g; 240 mmol) and 10percent Pd/C (3.14 g; 29 mmol) are added to a solution of 1-methyl-4-piperidone (3.26 mL; 26.5 mmol) in aqueous methanol (80 mL, CH3OH/H2O 9:1); the mixture is stirred for 24 h. at r.t.;. catalyst removal by filtration over Celite and solvent evaporation to dryness at low pressure give a pale yellow residue of 1-methyl-4-aminopiperidine. Dropwise addition of 37percent HCl (4,6 mL) to a stirred solution of said amine in EtOH (50 mL) separates a white precipitate of 1-methyl-4-aminopiperidine hydrochloride that is filteted 18 hrs later, after cooling for 18 hrs at T = + 4°C. Finally, an aqueous solution of the hydrochloride treated with an excess of 0,1 N NaOH (≈ 10 mL) is extracted with CH2Cl2 (3x10 mL). After the usual work-up, solvent evaporation to dryness yields pure 1-methyl-4-aminopiperidine (1.4 g; 12.4 mmol). 1H-NMR (CDCl3): δ 2.85 (m, 2H); 2.58 (m, 1H); 2.25 (s, 3H); 2.01 (m, 2H); 1.85 (m, 2H); 1.63 (bs, 2H, NH2); 1.47 (m, 2H).
Reference: [1] Patent: WO2012/59932, 2012, A1, . Location in patent: Page/Page column 137
[2] Tetrahedron Letters, 2001, vol. 42, # 25, p. 4257 - 4259
[3] Bioorganic and Medicinal Chemistry, 2008, vol. 16, # 8, p. 4390 - 4400
[4] Farmaco, 1998, vol. 53, # 3, p. 233 - 240
[5] Yakugaku Zasshi, 1951, vol. 71, p. 1053,1057[6] Chem.Abstr., 1952, p. 5044
[7] Patent: US2006/183769, 2006, A1, . Location in patent: Page/Page column 7
[8] Patent: EP1366018, 2016, B1, . Location in patent: Paragraph 0112
  • 6
  • [ 1445-73-4 ]
  • [ 41838-46-4 ]
YieldReaction ConditionsOperation in experiment
88% With hydrogenchloride; NaCNBH3 In methanol; diethyl ether a)
4-Amino-1-methylpiperidine
1-Methylpiperidin-4-one (4.22 g, 37 mmol) and an ice cold soln of 1N HCl in Et2 O (37 mL, 37 mmol) were combined.
Trituration followed by evaporation of the Et2 O at 23° under a stream of argon afforded the hydrochloride. MeOH (114 mL), anhydrous NH4 OAc (28.7, 373 mmol) and 3A molecular sieves were added.
Stirred 10 min and then NaCNBH3 (2.33 g; 37 mmol) was added, and the mixture was stirred for 1 h.
Acidified to 2 O.
The resulting mixture was made basic with 50percent aq NaOH and extracted with EtOAc, dried (K2 CO3), and distilled (bp=55°-60°, 15 mm) to afford 3.88 g (88percent) of the title compound.
88% With hydrogenchloride; NaCNBH3 In methanol; diethyl ether a)
4-Amino-1-methylpiperidine
1-Methylpiperidin-4-one (4.22 g, 37 mmol) and an ice cold soln of 1N HCl in Et2 O (37 mL, 37 mmol) were combined.
Trituration followed by evaporation of the Et2 O at 23° under a stream of argon afforded the hydrochloride. MeOH (114 mL), anhydrous NH4 OAc (28.7, 373 mmol) and 3A molecular sieves were added.
Stirred 10 min and then NaCNBH3 (2.33 g, 37 mmol) was added, and the mixture was stirred for 1 h.
Acidified to 2 O.
The resulting mixture was made basic with 50percent aq NaOH and extracted with EtOAc, dried (K2 CO3), and distilled (bp=55°-60°, 15 mm) to afford 3.88 g (88percent) of the title compound.
Reference: [1] Patent: US5593992, 1997, A,
[2] Patent: US5670527, 1997, A,
  • 7
  • [ 1445-73-4 ]
  • [ 74-89-5 ]
  • [ 73579-08-5 ]
Reference: [1] Journal of the Chemical Society, 1957, p. 3165,3171
[2] Patent: US6423713, 2002, B1,
[3] Patent: US6514977, 2003, B1,
  • 8
  • [ 1445-73-4 ]
  • [ 73579-08-5 ]
Reference: [1] Bioorganic and Medicinal Chemistry Letters, 2012, vol. 22, # 1, p. 347 - 352
  • 9
  • [ 1445-73-4 ]
  • [ 51304-64-4 ]
Reference: [1] Helvetica Chimica Acta, 1959, vol. 42, p. 533,539, 562
[2] Patent: US2865922, 1957, ,
  • 10
  • [ 106-52-5 ]
  • [ 1445-73-4 ]
Reference: [1] Angewandte Chemie - International Edition, 2014, vol. 53, # 12, p. 3236 - 3240[2] Angew. Chem., 2014, vol. 126, # 12, p. 3300 - 3304,5
[3] European Journal of Organic Chemistry, 2018, vol. 2018, # 39, p. 5427 - 5434
  • 11
  • [ 91-16-7 ]
  • [ 1445-73-4 ]
  • [ 82359-63-5 ]
Reference: [1] Patent: US4415736, 1983, A,
  • 12
  • [ 41661-47-6 ]
  • [ 74-88-4 ]
  • [ 1445-73-4 ]
Reference: [1] Patent: CN105985355, 2016, A, . Location in patent: Paragraph 0688; 0689; 0690; 0691
  • 13
  • [ 25012-72-0 ]
  • [ 1445-73-4 ]
Reference: [1] Journal of the American Chemical Society, 1948, vol. 70, p. 1826
[2] Journal of the Chemical Society, 1949, p. 708,712
  • 14
  • [ 6315-60-2 ]
  • [ 1445-73-4 ]
Reference: [1] Journal of the American Chemical Society, 1948, vol. 70, p. 1826
  • 15
  • [ 2949-22-6 ]
  • [ 1445-73-4 ]
Reference: [1] Patent: US6225311, 2001, B1,
  • 16
  • [ 41979-39-9 ]
  • [ 74-88-4 ]
  • [ 1445-73-4 ]
Reference: [1] ACS Medicinal Chemistry Letters, 2014, vol. 5, # 5, p. 506 - 511
  • 17
  • [ 13221-89-1 ]
  • [ 1445-73-4 ]
Reference: [1] Journal of Organic Chemistry, 1945, vol. 10, p. 277,278
[2] Yakugaku Zasshi, 1951, vol. 71, p. 1053,1057[3] Chem.Abstr., 1952, p. 5044
  • 18
  • [ 105-71-5 ]
  • [ 1445-73-4 ]
Reference: [1] Journal of Organic Chemistry, 1945, vol. 10, p. 277,278
  • 19
  • [ 15637-49-7 ]
  • [ 1445-73-4 ]
Reference: [1] Monatshefte fur Chemie, 2015, vol. 146, # 6, p. 973 - 981
  • 20
  • [ 3592-25-4 ]
  • [ 74-89-5 ]
  • [ 1445-73-4 ]
Reference: [1] Journal of the Chemical Society, 1952, p. 1164,1166
  • 21
  • [ 142080-50-0 ]
  • [ 1445-73-4 ]
  • [ 4726-84-5 ]
Reference: [1] Journal of Chemical Research, Miniprint, 1992, # 6, p. 1358 - 1370
  • 22
  • [ 74-89-5 ]
  • [ 1445-73-4 ]
Reference: [1] Tetrahedron, 2007, vol. 63, # 13, p. 2865 - 2874
  • 23
  • [ 76360-18-4 ]
  • [ 1445-73-4 ]
  • [ 67-56-1 ]
Reference: [1] Chemical and Pharmaceutical Bulletin, 1980, vol. 28, # 9, p. 2653 - 2657
  • 24
  • [ 1445-73-4 ]
  • [ 5355-68-0 ]
Reference: [1] Patent: EP2508526, 2012, A1,
[2] Patent: WO2012/130915, 2012, A1,
  • 25
  • [ 1445-73-4 ]
  • [ 5441-40-7 ]
Reference: [1] Journal of Organic Chemistry, 1949, vol. 14, p. 530,534
[2] Journal of Scientific and Industrial Research, 1958, vol. 17 B, p. 31
  • 26
  • [ 1445-73-4 ]
  • [ 116480-62-7 ]
  • [ 5192-03-0 ]
YieldReaction ConditionsOperation in experiment
48.9% With potassium hydroxide In methanol B.
Via 5-amino-1H-indole
To a solution of 1.29 gm (20 mMol) potassium hydroxide in 10 mL methanol were added 1.32 gm (10 mMol) 5-amino-lH-indole followed by 2.46 mL (20 mMol) 1-methyl-4-piperidone.
The reaction mixture was then heated to reflux for 18 hours.
The reaction mixture was cooled to ambient, diluted with 20 ml water and the precipitate collected by filtration.
The solid was recrystallized from ethyl acetate:methanol to give 1.11 gm (48.9percent) 5-amino-3-(1-methyl-1,2,3,6-tetrahydropyr-idin-4-yl)-1H-indole as a tan solid (m.p.=200-203°C).
The tan solid was subjected to flash chromatography, eluding with 100:20:0.5 dichloromethane:methanol:ammonium hydroxide, to give 0.99 gm 5-amino-3-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-1H-indole as a cream colored solid (m.p.=212-215°C (ethyl acetate:methanol)).
MS(m/e): 227(M+)
Calculated for C14H17N3: Theory: C, 73.98; H, 7.54; N, 18.49. Found: C, 73.76; H, 7.48; N, 18.22.
Reference: [1] Patent: EP824917, 1998, A2,
  • 27
  • [ 1445-73-4 ]
  • [ 40807-61-2 ]
Reference: [1] Pharmaceutical Chemistry Journal, 1987, vol. 21, # 1, p. 60 - 61
  • 28
  • [ 1445-73-4 ]
  • [ 100-63-0 ]
  • [ 5094-12-2 ]
YieldReaction ConditionsOperation in experiment
93%
Stage #1: With sulfuric acid In 1,4-dioxane at 0 - 60℃;
Stage #2: With sodium hydrogencarbonate; sodium hydroxide In 1,4-dioxane; water
[0216] 2-Methyl-2,3,4,5-tetrahydro-lH-pyrido[4,3-*]indole (17): Phenyl hydrazine (1.0 g, 9.3 mmols) and l-methyl-piperidin-4-one (1.1 g, 9.3 mmols) were dissolved in 1,4-dioxane (35 mL) and cooled to 0°C. Concentrated sulfuric acid (5 mL) was added dropwise to the reaction at O0C with stirring upon which a precipitate formed. The reaction was then heated to 60°C for one hour after which the precipitate was fully dissolved. The reaction was stirred for an additional hour at 60°C. The reaction was then cooled to room temperature and the pH was adjusted to approximately 12 by the addition of saturated aqueous sodium bicarbonate solution followed by small portions of solid sodium hydroxide. The organic products were extracted with chloroform (3x20 mL) and the combined organic extracts were washed with brine (15 mL), dried (Na2SO4) and concentrated in vacuo. Purification by columnchromatography (0-80percent gradient of ethyl acetate in hexane) afforded the final product (1.6 g, 93percent yield) as a beige solid. 1H NMR (400 MHz, DMSO): δ 10.80 (s, IH), 7.30 (m, 2H), 6.98 (m, 2H), 3.53 (s, 2H), 2.79 (t, J= 5.2 Hz, 2H), 2.71 (t, 2H, J= 5.4 Hz), 2.43 (s, 3H). 13C NMR APT (100 MHz, CDCl3): S 136.2 (up), 132.0 (up), 126.0 (up), 121.0 (down), 119.1 (down), 117.4 (down), 110.7 (down), 108.3 (up), 52.5 (up), 51.8 (up), 45.8 (down), 23.5 (up). ESI-HRMS (m/z): [M+H]+ calcd. for C12H14N2, 187.1230; found, 187.1228
7 g With hydrogenchloride In water at 55℃; for 48 h; To a suspension of phenylhydrazine (5.4 g) in 75 mL water was added slowly 4.2 mL of 12 N HCI, followed by addition of 1 -methylpiperidin-4-one (6.7 g). Additional 16 g of 12N HCI was added and the reaction mixture was heated at 55 oC for 2 days. After cooling in a ice-water bath, 10 N NaOH solution was added slowly until pH >12. 20 g of NaCI was added to the mixture and the reaction mixture was extracted with 2 x 100 mL of CH2CI2. The combined extracts were dried over Na2S04, filtered and concentrated. The residue was swished from EtOAc to give 7 g of the title compounds as a light yellow solid.[00111] Step 2 methyl 4-((2-methyl-1 ,2,3,4-tetrahydropyrimido[1 ,6- a]indol-5-yl)thio)benzoate
Reference: [1] Journal of the American Chemical Society, 2010, vol. 132, # 31, p. 10842 - 10846
[2] Patent: WO2011/11186, 2011, A2, . Location in patent: Page/Page column 51
[3] Organic Letters, 2018, vol. 20, # 6, p. 1589 - 1592
[4] Tetrahedron Letters, 2004, vol. 45, # 24, p. 4781 - 4783
[5] Patent: WO2013/78544, 2013, A1, . Location in patent: Paragraph 00109-00110
[6] RSC Advances, 2016, vol. 6, # 60, p. 54918 - 54925
  • 29
  • [ 1445-73-4 ]
  • [ 5094-12-2 ]
Reference: [1] Patent: CN108558905, 2018, A, . Location in patent: Paragraph 0047; 0049-0051
  • 30
  • [ 1445-73-4 ]
  • [ 108-42-9 ]
  • [ 5094-12-2 ]
Reference: [1] Journal of Heterocyclic Chemistry, 2015, vol. 51, # 5, p. 1257 - 1263
  • 31
  • [ 1445-73-4 ]
  • [ 5094-12-2 ]
Reference: [1] Journal of the Chemical Society, 1945, p. 399,401
  • 32
  • [ 1445-73-4 ]
  • [ 591-51-5 ]
  • [ 4972-68-3 ]
Reference: [1] Journal of the American Chemical Society, 1950, vol. 72, p. 3134,3135
[2] Patent: DE872045, 1941, ,
[3] Dansk Tidsskrift for Farmaci, 1943, vol. 17, p. 173,180
[4] Journal of Organic Chemistry, 1947, vol. 12, p. 894,897, 9O2
[5] Journal of the American Chemical Society, 1950, vol. 72, p. 3134,3135
[6] Patent: DE872045, 1941, ,
[7] Dansk Tidsskrift for Farmaci, 1943, vol. 17, p. 173,180
[8] Journal of Organic Chemistry, 1947, vol. 12, p. 894,897, 9O2
[9] Journal of Medicinal Chemistry, 1986, vol. 29, # 3, p. 424 - 427
[10] Antioxidants and Redox Signaling, 2015, vol. 23, # 13, p. 1001 - 1016
  • 33
  • [ 1445-73-4 ]
  • [ 108-86-1 ]
  • [ 4972-68-3 ]
Reference: [1] Patent: US4132710, 1979, A,
  • 34
  • [ 1445-73-4 ]
  • [ 4972-68-3 ]
Reference: [1] Journal of the American Chemical Society, 1950, vol. 72, p. 3134,3135
[2] Patent: DE872045, 1941, ,
[3] Dansk Tidsskrift for Farmaci, 1943, vol. 17, p. 173,180
[4] Journal of Organic Chemistry, 1947, vol. 12, p. 894,897, 9O2
[5] Journal of the American Chemical Society, 1950, vol. 72, p. 3134,3135
[6] Patent: DE872045, 1941, ,
[7] Dansk Tidsskrift for Farmaci, 1943, vol. 17, p. 173,180
[8] Journal of Organic Chemistry, 1947, vol. 12, p. 894,897, 9O2
[9] Medicinal Chemistry Research, 2004, vol. 13, # 6-7, p. 518 - 527
  • 35
  • [ 1445-73-4 ]
  • [ 71-43-2 ]
  • [ 106-52-5 ]
  • [ 4972-68-3 ]
Reference: [1] Journal of the American Chemical Society, 1950, vol. 72, p. 3134,3135
  • 36
  • [ 1445-73-4 ]
  • [ 95533-25-8 ]
Reference: [1] Patent: EP581538, 1994, A1,
  • 37
  • [ 1445-73-4 ]
  • [ 95533-25-8 ]
Reference: [1] Bioorganic and Medicinal Chemistry Letters, 1996, vol. 6, # 15, p. 1825 - 1830
  • 38
  • [ 1445-73-4 ]
  • [ 541-41-3 ]
  • [ 29976-53-2 ]
Reference: [1] Pharmaceutical Chemistry Journal, 1987, vol. 21, # 1, p. 60 - 61
[2] Organic Process Research and Development, 2018, vol. 22, # 1, p. 91 - 96
  • 39
  • [ 1445-73-4 ]
  • [ 29976-53-2 ]
Reference: [1] Tetrahedron Letters, 1988, vol. 29, # 27, p. 3303 - 3306
  • 40
  • [ 1445-73-4 ]
  • [ 89167-34-0 ]
Reference: [1] Journal of Organic Chemistry, 2006, vol. 71, # 22, p. 8602 - 8609
  • 41
  • [ 1445-73-4 ]
  • [ 23007-85-4 ]
Reference: [1] Antioxidants and Redox Signaling, 2015, vol. 23, # 13, p. 1001 - 1016
  • 42
  • [ 1445-73-4 ]
  • [ 74-88-4 ]
  • [ 26822-37-7 ]
YieldReaction ConditionsOperation in experiment
88% at 0 - 20℃; for 1 h; Step 1: Preparation of 1,1-dimethyl-4-oxopiperidinium iodide [Show Image] Methyl iodide (1.6 mL, 26.5 mmol) was added into a solution of 1-methyl-piperidin-4-one (2.0 g, 17.6 mmol) in acetone (10 mL) at 0 °C. The reaction mixture was stirred at room temperature for 1 hour. The precipitate was filtered off and washed with acetone to afford the title compound as an off-white solid (4.0 g, 88 percent). 1H NMR (D2O, 400 MHz): δ 3.38 (t, J=5.8 Hz, 4H), 3.06 (s, 6H), 1.95-2.05 (m, 4H). LCMS (Method D): Mass found (M+ 128.2), Rt (min): 1.19, Area (percent): 95.3 (Max. Chrom.)
88% at 0 - 20℃; for 1 h; Step 1: Preparation of 1,1-dimethyl-4-oxopiperidinium iodideMethyl iodide (1.6 mL, 26.5 mmol) was added into a solution of 1-methyl-piperidin-4-one (2.0 g, 17.6 mmol) in acetone (10 mL) at 0 °C. The reaction mixture was stirred at room temperature for 1 hour. The precipitate was filtered off and washed with acetone to afford the title compound as an off-white solid (4.0 g, 88 percent). 1H NMR (D20, 400 MHz): δ 3.38 (t, J=5.8 Hz, 4H), 3.06 (s, 6H), 1.95-2.05 (m, 4H). LCMS (Method D): Mass found (M+ 128.2), Rt (min): 1.19, Area (percent): 95.3 (Max. Chrom.)
Reference: [1] Journal of Organic Chemistry, 2006, vol. 71, # 22, p. 8602 - 8609
[2] Journal of Organic Chemistry, 2014, vol. 79, # 8, p. 3358 - 3373
[3] Organic Process Research and Development, 2004, vol. 8, # 6, p. 939 - 941
[4] Angewandte Chemie - International Edition, 2008, vol. 47, # 32, p. 5968 - 5972
[5] Journal of the American Chemical Society, 2009, vol. 131, # 1, p. 357 - 367
[6] Patent: EP2508526, 2012, A1, . Location in patent: Page/Page column 45
[7] Patent: WO2012/130915, 2012, A1, . Location in patent: Page/Page column 55
[8] Journal of Organic Chemistry, 1945, vol. 10, p. 277,278
[9] Journal of the American Chemical Society, 1949, vol. 71, p. 465
[10] Journal of the Chemical Society, 1949, p. 708,712
[11] Journal of the Chemical Society, Perkin Transactions 2: Physical Organic Chemistry (1972-1999), 1984, # 10, p. 1647 - 1652
[12] Patent: WO2005/90333, 2005, A1, . Location in patent: Page/Page column 135
[13] Patent: CN105985355, 2016, A, . Location in patent: Paragraph 0692; 0693; 0694; 0695
  • 43
  • [ 1445-73-4 ]
  • [ 108-20-3 ]
  • [ 74-88-4 ]
  • [ 26822-37-7 ]
Reference: [1] Patent: US6884868, 2005, B1,
  • 44
  • [ 1445-73-4 ]
  • [ 74-88-4 ]
  • [ 26822-37-7 ]
  • [ 26822-30-0 ]
Reference: [1] Journal of Organic Chemistry, 2005, vol. 70, # 5, p. 1930 - 1933
  • 45
  • [ 1445-73-4 ]
  • [ 75-03-6 ]
  • [ 77542-18-8 ]
YieldReaction ConditionsOperation in experiment
86% at 20℃; for 4 h; EXAMPLE 55 Synthesis of (f?)-3-chloro-4-((1 -(1 -phenylethyl)piperidin-4-yl)oxy)-/V-(thiazol-2- yl)benzenesulfonamide 2,2,2-trifluoroacetate Step 1. Preparation of 1-ethyl-1-methyl-4-oxopiperidin-1-ium iodide To a solution of 1-methylpiperidin-4-one (13.8 mL, 120 mmol) in butan-2-one (70 mL) was added iodoethane (10.6 mL, 132 mmol) and the reaction mixture was stirred at ambient temperature for 4 d. The mixture was filtered and the resulting solid was dried in vacuo to afford the title compound as an orange solid (27.8 g, 86percent yield): H NMR (300 MHz, D20) £3.52-3.38 (m, 6H), 3.05 (s, 3H), 2.17-1.99 (m, 4H), 1.34 (t, J = 7.3 Hz, 3H); MS (ES+) m/z 142.2 (M + 1).
Reference: [1] Green Chemistry, 2017, vol. 19, # 3, p. 614 - 618
[2] ChemMedChem, 2015, vol. 10, # 7, p. 1249 - 1258
[3] Patent: WO2017/201468, 2017, A1, . Location in patent: Page/Page column 163
[4] Organic Process Research and Development, 2012, vol. 16, # 1, p. 109 - 116
[5] Bioorganic and Medicinal Chemistry, 2010, vol. 18, # 21, p. 7675 - 7699
  • 46
  • [ 1445-73-4 ]
  • [ 113225-10-8 ]
Reference: [1] Tetrahedron, 1988, vol. 44, # 7, p. 2081 - 2086
  • 47
  • [ 1445-73-4 ]
  • [ 216966-37-9 ]
Reference: [1] Synthetic Communications, 2001, vol. 31, # 5, p. 787 - 797
[2] Patent: WO2018/2219, 2018, A1,
  • 48
  • [ 1445-73-4 ]
  • [ 143150-92-9 ]
Reference: [1] Patent: US2013/144061, 2013, A1,
[2] Patent: US2017/50983, 2017, A1,
  • 49
  • [ 1445-73-4 ]
  • [ 454482-11-2 ]
Reference: [1] Patent: CN105566367, 2016, A,
Same Skeleton Products
Historical Records

Related Functional Groups of
[ 1445-73-4 ]

Ketones

Chemical Structure| 77542-18-8

[ 77542-18-8 ]

1-Ethyl-1-methyl-4-oxopiperidin-1-ium iodide

Similarity: 0.96

Chemical Structure| 5355-68-0

[ 5355-68-0 ]

1-Isopropyl-4-piperidone

Similarity: 0.92

Chemical Structure| 72544-16-2

[ 72544-16-2 ]

1-Isobutylpiperidin-4-one

Similarity: 0.92

Chemical Structure| 19869-42-2

[ 19869-42-2 ]

1-Methylazepan-4-one hydrochloride

Similarity: 0.88

Chemical Structure| 41979-39-9

[ 41979-39-9 ]

Piperidin-4-one hydrochloride

Similarity: 0.88

Related Parent Nucleus of
[ 1445-73-4 ]

Piperidines

Chemical Structure| 77542-18-8

[ 77542-18-8 ]

1-Ethyl-1-methyl-4-oxopiperidin-1-ium iodide

Similarity: 0.96

Chemical Structure| 5355-68-0

[ 5355-68-0 ]

1-Isopropyl-4-piperidone

Similarity: 0.92

Chemical Structure| 72544-16-2

[ 72544-16-2 ]

1-Isobutylpiperidin-4-one

Similarity: 0.92

Chemical Structure| 320589-77-3

[ 320589-77-3 ]

Piperidin-4-one hydrochloride hydrate

Similarity: 0.88

Chemical Structure| 41979-39-9

[ 41979-39-9 ]

Piperidin-4-one hydrochloride

Similarity: 0.88